Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


JAMA Studies Provide More Ammunition For Trial Disclosure Reformers

This article was originally published in The Pink Sheet Daily

Executive Summary

JAMA studies focus on the high number of terminated and unreported trials, plus discrepancies in publicly reported trial results. Publication comes as the Institute of Medicine consults stakeholders about trial data sharing and ahead of new reporting laws in Europe.


Related Content

FDA Post-Marketing Study Compliance Efforts To Get HHS OIG Review
J&J’s Clinical Data Disclosure Strategy Focuses On Collaboration With Yale University Group
IOM Plans Study To Facilitate Clinical Trial Data Sharing
Clinical Trials Transparency: EMA Delay Gives Industry Initiative More Time To Take Root
GSK Champions More Trial Data Disclosure, But PhRMA Objects Compliance: Absent Regs, Enforcement Of Reporting Still Lags


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts